Freenome Sinks 11% Despite “Clinically Meaningful” Gains for Next-Gen Colon Cancer Blood Test

Data ReadoutpositiveNext-Gen Colon Cancer Blood TestNegative

AI Analysis

Summary

Freenome reported clinically meaningful gains for its next-generation colon cancer blood test, though the stock declined 11% following the announcement.

Outcome Details

Clinically meaningful gains reported for next-generation colon cancer blood test

Importance:5/10

Sentiment:

-0.30

colon cancerblood testliquid biopsyearly detection

Related Companies

$ABT

Read the original article

Published by yahoo_finance on October 13, 2026 12:20 PM

Read Original